| 4591 |
株式会社会リボミック
|
M&A |
|
Domestic Phase 3 Clinical Trial of Omedaptanib Pegol for Achondroplasia: Announcement of Expanded Investigational Sites
|
Aug 3, 2026
|
| 4578 |
Otsuka Holdings Co., Ltd.
|
Share Buyback |
|
Notice Regarding Share Buyback Status
|
Aug 3, 2026
|
| 4571 |
NANO Holdings Co., Ltd.
|
Stock Option |
|
Notification on Monthly Exercise Status of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Provisions)
|
Aug 3, 2026
|
| 4569 |
Kyorin Pharmaceutical Co., Ltd.
|
Other |
|
Promotion activities for the allergy conjunctivitis treatment ‘Allegion® Eyelid Cream 0.5%’
|
Aug 3, 2026
|
| 4544 |
H.U. Group Holdings Co., Ltd.
|
Share Buyback |
|
News Regarding Share Buyback Activities
|
Aug 3, 2026
|
| 4523 |
Eisai Co., Ltd. (Eisai Co., Ltd.)
|
Earnings |
|
Financial Summary for the First Quarter of Fiscal Year 2026
|
Aug 3, 2026
|
| 4523 |
Eisai Co., Ltd.
|
Earnings |
|
FY2026 Q1 Consolidated IFRS Financial Results
|
Aug 3, 2026
|
| 4523 |
Eisai Co., Ltd.
|
Earnings |
|
First Quarter Financial Results for Fiscal Year Ending March 2027 IFRS (Consolidated) [Supplement: Financial Results Summary Document]
|
Aug 3, 2026
|
| 4507 |
Shionogi & Co., Ltd.
|
Earnings |
|
[Shionogi & Company] 2026 First Quarter Results and HIV Business Update Materials
|
Aug 3, 2026
|
| 4507 |
Shionogi & Co., Ltd.
|
Earnings |
|
Q1 FY2027 Financial Results Supplement
|
Aug 3, 2026
|
| 4507 |
Shionogi & Co., Ltd.
|
Earnings |
|
Shionogi & Co., Ltd. Q1 Financial Summary (IFRS) for the Fiscal Year Ending March 2027 | April 1, 2026 to June 30, 2026
|
Aug 3, 2026
|
| 4394 |
Exmotion
|
Personnel |
|
Notice Regarding Executive Changes
|
Aug 3, 2026
|
| 4388 |
エーアイ
|
Other |
|
Notice Regarding Repurchase of Company Shares
|
Aug 3, 2026
|
| 4287 |
Just Planning Co., Ltd.
|
Share Buyback |
|
Notice Regarding the Status of Share Buyback
|
Aug 3, 2026
|
| 4264 |
SECURE
|
Strategy |
|
Notice on Completion of Payment for New Shares Issued as Restricted Stock
|
Aug 3, 2026
|
| 4151 |
Kowa Kirin Company, Limited
|
Earnings |
|
Financial Summary Supplement — Interim Financial Results for the Fiscal Year Ending December 2026, Q2
|
Aug 3, 2026
|
| 4151 |
Kowa Kirin Co., Ltd.
|
Earnings |
|
Kowa Kirin Co., Ltd. 2026 Fiscal Year December Interim (Six-Month) Financial Summary [IFRS] (Consolidated)
|
Aug 3, 2026
|
| 4118 |
Kaneka Corporation
|
Share Buyback |
|
Notice on the Status of Share Buyback
|
Aug 3, 2026
|
| 4005 |
Sumitomo Chemical Company, Limited
|
Strategy |
|
Notice regarding the confirmation of the amount of capital surplus decreasing due to the stock swap and the transfer to primary capital surplus
|
Aug 3, 2026
|
| 3970 |
イノベーション
|
Other |
|
Notice on Monthly Exercise Status of the 8th and 9th Stock Acquisition Rights (Exercise Price Adjustment Clause) Issued via Third-Party Allotment
|
Aug 3, 2026
|
